Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 2	2025-08-21		NCT06599216

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Harbin Medical University	42

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Harbin Medical Cancer Hospital	Harbin	China	1
Harbin Medical University Cancer Hospital	Harbin	China	51

Clinical trials